NEW POSSIBILITIES IN PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC VEIN COMPLICATIONS IN OBSTETRICS
DOI:
https://doi.org/10.11603/24116-4944.2009.1.9655Keywords:
thromboembolic vein complications, pregnancy, low-molecular heparinAbstract
First specimen of a new generation of low- molecular heparin bemyparin was applied with a prophylactic purpose after caesarean sections at 24 women with middle and high risk of thromboembolic vein complications and at 5 pregnant women with a deep ileophemoral thrombosis (4), artificial heart valve (1). Fora prophylaxis if mass of body of pregnant women was less than 70 kg and middle degree of risk gave 2500 МЕ/day, if mass was more than 70 kg or high risk -3500 МЕ/day. The prophylacsis began in 6 hours after operation and continued 3-7 days. For treatment of bemyparin gave 3500 МЕ/day during 2-5 weeks. Cases of pulmonary embolism, other tromboembolic vein complications were not present. The abundant bleeding was not present. The insignificant bleeding is marked in 2 cases (6, 9 %), hemorrhage in places of injections - in 12 cases (41,4%). Other complications of bemyparin therapy (thrombocytopeia, hyperkaliemia) were not observed. A conclusion about high prophylactic efficiency and safety of bemyparin in obstetric practice is done.
References
Obstetrics: The Californian Uni-Vorostate / Pod. Ed. K. Nischwander, A. Evans (per English.) - Moscow: Practice, 1999. - 703 p.
What is the number? Investigation of cases maternal mortality and complications for purposes ensuring pregnancy safety. T.1. - Geneva: World Health Organization, 2003.
Strategies to reduce pregnancy-related deaths: from identification and review to action / Ed. by C. Berg, I. Danel, H. Atrash et al. - Atlanta: Centers for Disease Control and Prevention, 2001.
Why Mothers Die 1997-1999: The Fifth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom - London: Royal College of Obstetrics and Health Gynaecologists Press, 2001.
Zhilka N.Ya., Medved VI, Leush S.S. etc. Analysis the main causes of death of women associated with pregnancy in Ukraine in 2007 and ways to solve the problem // Medi-social problems of the seven '. - 2008. - No. 1-2. - P. 3-18
Medved VI, Islamova O.V., Danilkov O.O. Cardiovascular vascular disease as the cause of maternal death // Topical issues of pediatrics, obstetrics and gynecology. - 2008. -№2.-С 65-69.
Order of the Ministry of Health of Ukraine dated June 15, 2007 No. 329 «On Approval clinical protocols for medical assistance for the prevention of thrombotic complications in surgeons, orthopedists and traumatologists, obstetrics and gynecologists» Ki in 2007.
Planes A., Vochelle N., Gonzalez De Suso M.J., Clarag J.P. Profilaxis antitrombotica posciruha ortopedica con bemiparin, heparina de bajo peso molecular de segumda generacion // Rev. Anesthesiol Reanim - 2001 / -V. 48.-p. 258-263.
Navarro-Quilis A., Castellet E., Rocha E. et al. Efficacy and the satety of bemiparin compared with enoxaparin prevention of venous thromboembolism afte total knee arthroplasty. A randomized doubleblind clinical trial // J. Thromb Haemost -2003. -V 1 - p. 425-432.
Kakkar W., Gedsk M., Kadziola Z. et al. Lowmolecular-weight of heparin in the acute and long-term treatment of deep-vein thrombosis // Thromb. Haemost -2003 -V 89. - pp. 674-680.
Gomez-Outes A., Rocha E., Martinez-Gonzalez J., Kakkar V.V. Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acuteand long-term treatment of deep vein th rom b o s is // Pharmacoeconomics. - 2006. - P. 24. - P. 81-92.
Santamaria A., Juarez S., Reche A. et al. Lowmolecular-weight heparin, bemiparin, in the oupatiant tre a tm e n t and se c o n d a ry p ro p h y la x is o f venous Thromboembolism in the standard clinical practice: the ESFERA study // Int. J. Clin. Pract - 2006. - V. 60. - P. 518-525.
Lecumberri R., Rosario E., Pacho J., Rocha E. Fixeddose low-molecular-weight heparin, bemiparin, in the longterm treatment of venous thromboembolism in patients with transient riskfactors in stamdard clinical practice: the FLEBUS study // J. Thromb. Haemost - 2006. - V.4. - pp. 25042508.
Hernando E.R. B im ip a rin (Hibor®) in Thromboembolic Venous Disease and other Clinical Situations. // Madrid: 2008. Grupo Acciyn Mndica. 212 p.
Santamama A., Vilea J, Marco A. et al. Clinical management using low-molecular-weight heparin (LMWH) in pregnant women with thrombophilia, thromboembolic disease (DVT) or thrombophilia-related maternoplacental syndrome: experience in one center // J. Thromb Haemost - 2007 -V 5 (suppl 2). - P.W-587 (abstract).
Zapatero J., Canut L., Reig V. et al. Absence of embryofetal-toxicity in rats and rabbits following s.c. administration of bemiparin // Meth. Find Exp. Clin Pharmacol - 2004 26 (suppl A). - P-1-30 (abstract).
Colligmon F., Frydman A., Caplain H. et al. Comparison of the pharmacokinetic profiles of three low molecular masses heparins - dalteparin, enoxaparin, nadroparin – administered subcutaneously in heathy volunteers (doses for prevention of thromboembolism) // Thromb. Haemost - 1995. -V.77. -P.630-640.
Borrell M., Antonijoan R. M., Ortin R. et al. Phar / Ackinetic profiles of two LMWH: Bemiparin 3.500 IU and Enoxaparin 4,000 IU after subcutaneous administration healthy volunteers // Thromb. Haemost.- 2001.-V. 86, Suppl: CD3578 (Abstract).
Perez-RuizA., Montes R., Carrasco P., Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin are hemostatic properties of Endothelium // Clin. Appl. Thromb Hemost -2 0 0 2. -V 8 - P.65-71.
Martinez-Gonzales J., Vila L., RodriguezC. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboe mbolism // ExpertReview of Cardiovascular Therapy. - 2008. - V.6, No. 6. - P.793-802.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
